Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice

Clinical Microbiology and Infection

Volumn 18, Issue 6, 2012, Pages 606-612

  Symons, J ^a   Vandekerckhove, L ^b   Paredes, R ^c   Verhofstede, C ^b   Bellido, R ^c   Demecheleer, E ^b   van Ham, P M ^a   van Lelyveld, S F L ^a   Stam, A J ^a   van Versendaal, D ^a   Nijhuis, M ^a   Wensing, A M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c IrsiCaixa Foundation   (Spain)

Author keywords

CCR5; CXCR4; Genotypic; HIV 1; Maraviroc; R5 tropic; Tropism; X4 tropic

Indexed keywords

GLYCOPROTEIN GP 120; MARAVIROC; VIRUS DNA; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLICATE TESTING; VIRAL GENETICS; VIRAL TROPISM; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860992262     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03631.x     Document Type: Article

References (22)

1. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732.
2. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
3. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 2009; 3: 94-102.
4. Saag M, Heera J, Goodrich J et al. Reanalysis of the MERIT Study with the Enhanced Trofile Assay (MERIT-ES). 2008. 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA.
5. Chan SY, Speck RF, Power C, Gaffen SL, Chesebro B, Goldsmith MA. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol 1999; 3: 2350-2358.
6. Jensen MA, van't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 2: 104-112.
7. Vandekerckhove LPR, Wensing AMJ, Kaiser R et al. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing. Lancet 2011; 11: 394-407.
8. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug-resistance mutations by automated DNA-sequencing. Nature 1993; 365: 671-673.
9. Leitner T, Halapi E, Scarlatti G et al. Analysis of heterogeneous viral populations by direct DNA-sequencing. BioTechniques 1993; 1: 120-127.
10. Vandenbroucke I, Van Eygen V, Rondelez E, Van Baelen K, Stuyver LJ. Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays. Antivir Ther 2007; 12: S154.
11. McGovern PR, Dong W, Zhong X et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to Maraviroc of treatment-naïve patients in the MERIT Trial. 2010. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA. Abstract 92.
12. Hahn BH, Shaw GM, Taylor ME et al. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 1986; 232: 1548-1553.
13. Swenson LC, Knapp D, Harrigan PR. Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype. 2010. Tenth International Congress on Drug Therapy in HIV Infection Glasgow. Abstract O122.
14. Strang A, Cameron J, Booth C, Garcia Diaz A, Geretti AM. Genotypic prediction of viral co-receptor tropism: correlation with enhanced Trofile. 7th European HIV Drug Resistance Workshop. Stockholm, Sweden; 2009. Abstract 80. Reviews in Antiviral Therapy 1:85-86.
15. Van Lelyveld SFL, Symons J, Hoepelman AIM et al. Correlation of clinical outcome of maraviroc treatment with different methods to determine HIV tropism: genotypic assay, MT-2 assay and Trofile. 2010. 8th European HIV Drug Resistance Workshop, Sorrento, Italy. Abstract 41.
16. Recordon-Pinson P, Soulie C, Flandre P et al. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 2010; 54: 3335-3340.
17. Obermeier M, Carganico A, Bieniek B, Schleehauf D, Dupke S, Fischer K. Tropism testing from proviral DNA-analysis of a subgroup from the Berlin Maraviroc cohort. Rev Antivir Ther 2010; 1: 23.
18. de Oliveira T, Deforche K, Cassol S et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 19: 3793-3800.
19. Rhee SY, Fessel WJ, Liu TF et al. Predictive value of HIV-genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200: 453-463.
20. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-2525.
21. Raymond S, Recordon-Pinson P, Saliou A et al. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. J Antimicrob Chemother 2011; 66: 1972-1975.
22. Saag M, Goodrich J, Fätkenheuer G et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199: 1638-1647.